NCT00357786View on ClinicalTrials.gov

An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

December 31, 2008

Conditions
Fabry Disease
Interventions
DRUG

Replagal agalsidase alfa

DRUG

Replagal

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT00357786 - An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease | Biotech Hunter | Biotech Hunter